Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
HPTN 102: LEN in Women (HIV Prevention Medication)
Phase 2
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
MVT-601A-006 MOXIE
The primary objective of this study is to characterize changes in bone mineral density (BMD) during continuous treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) for up to 48 months (4 years) in two cohorts: (1) premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and (2) premenopausal women with moderate to severe pain associated with endometriosis.
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)
Phase 3
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)
The REMBRANDT Study (Recovery of the Microbiome from Antibiotics for Dental Implants)
The purpose of the study is to determine whether owning a pet changes the disruption and recovery of a person's microbiome (collection of bacteria in the intestines) following a course of antibiotics after they have received dental implant treatment.
The FIRE Trial: Reducing patient memory recall in the burning mouth patient population
The purpose of this study is to collect real-time data, such as pain symptoms and exercise habits, to investigate the factors that influence burning mouth symptoms.
Participants will be asked to complete questionnaires during the in-person visits and you will receive up to three, random daily notifications
from your smartphone to answer a series of questions. In total, the questions
in the survey will take approximately less than 1 minute to answer. Participation will last for about 12 weeks.
Potential maximum compensation of $190
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
